TerminatedNCT03547297
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Studying Acute hepatic porphyria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alnylam Pharmaceuticals
- Principal Investigator
- Quinn Dinh, MDAlnylam Pharmaceuticals
- Enrollment
- 212 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2018 – 2019
Study locations (12)
- Clinical Trial Site, Pasadena, California, United States
- Clinical Trial Site, Jacksonville, Florida, United States
- Clinical Trial Site, Margate, Florida, United States
- Clinical Trial Site, Ames, Iowa, United States
- Clinical Trial Site, Las Vegas, Nevada, United States
- Clinical Trial Site, Manhasset, New York, United States
- Clinical Trial Site, Winston-Salem, North Carolina, United States
- Clinical Trial Site, Pittsburgh, Pennsylvania, United States
- Clinical Trial Site, Pottsville, Pennsylvania, United States
- Clinical Trial Site, Knoxville, Tennessee, United States
- Clinical Trial Site, Houston, Texas, United States
- Clinical Trial Site, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03547297 on ClinicalTrials.govOther trials for Acute hepatic porphyria
Additional recruiting or active studies for the same condition.